Study guide

7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies

Key Takeaways Explain This Topic AI

Unfractionated Heparin (UFH) produces an equivalent 1:1 anti-IIa:anti-Xa ratio via antithrombin activation and is monitored by aPTT (1.5–2.5x baseline) or chromogenic anti-Xa (0.3–0.7 IU/mL), with complete reversal achieved using protamine sulfate (1 mg per 100 U UFH).

Low-Molecular-Weight Heparins (enoxaparin, dalteparin) exhibit a selective 3:1 to 4:1 anti-Xa:anti-IIa ratio and do not alter PT or aPTT; therapeutic monitoring in renal failure, pregnancy, or extreme weight relies exclusively on peak chromogenic anti-Xa assays drawn 4 hours post-dose (0.6–1.0 IU/mL for BID dosing; 1.0–2.0 IU/mL for daily dosing).

Direct Oral Anticoagulants (DOACs) include direct FXa inhibitors (rivaroxaban, apixaban, edoxaban), reversed by the decoy protein andexanet alfa, and the direct thrombin inhibitor dabigatran, monitored by dilute Thrombin Time (dTT) or Ecarin Clotting Time (ECT) and reversed specifically by the Fab antibody fragment idarucizumab.

Warfarin antagonizes VKORC1 to prevent gamma-carboxylation of Factors II, VII, IX, X, Protein C, and Protein S, monitored via PT/INR (target 2.0–3.0 for standard VTE/AFib; 2.5–3.5 for mechanical mitral valves), and reversed urgently with 4-Factor Prothrombin Complex Concentrate (4F-PCC) combined with intravenous Vitamin K1 (phytonadione).

Parenteral direct thrombin inhibitors (argatroban, bivalirudin) do not cross-react with PF4 antibodies, serving as the first-line anticoagulation standard in acute Heparin-Induced Thrombocytopenia (HIT) where warfarin is strictly contraindicated until platelet count recovery.

Last updated: August 2026

Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies

Anticoagulant pharmacotherapy is essential for the prevention and treatment of arterial and venous thromboembolism. Because anticoagulants carry narrow therapeutic windows, precise laboratory monitoring and rapid reversal strategies for life-threatening hemorrhage or emergent invasive procedures are fundamental responsibilities of the clinical hemostasis laboratory. [ ANTICOAGULANT TARGET ARCHITECTURE ]

  • INDIRECT (Antithrombin-Dependent) DIRECT (Enzyme Active Site)
  • ───────────────────────────────── ───────────────────────────
  • Unfractionated Heparin (UFH) ──► AT ──► Inactivates IIa & FXa (1:1 Ratio)
  • LMWH (Enoxaparin/Dalteparin) ──► AT ──► Inactivates FXa > IIa (4:1 Ratio)
  • Fondaparinux (Pentasaccharide)──► AT ──► Exclusively Inactivates FXa
  • Direct FXa Inhibitors (DOACs)
  • Rivaroxaban, Apixaban, Edoxaban
  • │
  • ▼
  • Direct Thrombin (IIa) Inhibitors
  • Oral: Dabigatran
  • Parenteral: Argatroban, Bivalirudin
  • VITAMIN K ANTAGONISTS
  • ─────────────────────
  • Warfarin ──► Inhibits VKORC1 ──► Blocks γ-Carboxylation of FII, FVII, FIX, FX, Protein C & S
  • Heparin and Heparinoid Anticoagulants [ HEPARIN CHAIN LENGTH DYNAMICS ]
  • UNFRACTIONATED HEPARIN (UFH)
  • [ Pentasaccharide ] ───────────── (≥ 18 Saccharides) ───────────── [ Thrombin Binding ]
  • │ │
  • ▼ ▼
  • Antithrombin Thrombin (IIa)
  • (Inactivates FXa) ◄────────────────────────────────────────────────► (Inactivates IIa)
  • ANTI-IIa : ANTI-Xa = 1 : 1
  • LOW-MOLECULAR-WEIGHT HEPARIN (LMWH)
  • [ Pentasaccharide ] ──── (< 18 Saccharides, Too Short to Bridge) ──── [ No Thrombin Bridging ]
  • │
  • ▼
  • Antithrombin (Inactivates FXa) Thrombin Unbound
  • ANTI-Xa : ANTI-IIa = 4 : 1
  • 1. Unfractionated Heparin (UFH)

Molecular Structure & Mechanism: Heterogeneous mixture of sulfated glycosaminoglycans (molecular weight 3,000 to 30,000 Da; mean ~15,000 Da). A specific unique pentasaccharide sequence present on ~one-third of heparin molecules binds Antithrombin (AT) , inducing an allosteric conformational transition that accelerates AT-mediated inhibition of Thrombin (Factor IIa) and Factor Xa by ~1,000-fold . To inhibit thrombin, heparin must form a ternary bridging complex encompassing both AT and thrombin simultaneously (requiring a polymer chain length of ≥ 18 \ge 18 ≥ 18 saccharide units ). This confers an equivalent 1 : 1 1:1 1 : 1 anti-Factor IIa to anti-Factor Xa activity ratio .

Laboratory Monitoring:

Activated Partial Thromboplastin Time (aPTT): Traditional method; target therapeutic range historically defined as 1.5 to 2.5 1.5\text{ to }2.5 1.5 to 2.5 times the laboratory's mean normal baseline (typically 60 to 85 seconds ). However, aPTT responsiveness is distorted by variable reagent sensitivity, elevated Factor VIII / fibrinogen (acute phase reactants causing heparin resistance), and baseline lupus anticoagulants.

Chromogenic Anti-Xa Assay (UFH-Calibrated): The modern gold standard. Patient plasma is incubated with excess bovine/human Factor Xa. Residual uninhibited FXa cleaves a chromogenic peptide substrate, releasing yellow p -nitroaniline ( p NA) measured at 405 nm 405\text{ nm} 405 nm (absorbance is inversely proportional to heparin concentration). Therapeutic Target: 0.3 to 0.7 IU/mL 0.3\text{ to }0.7\text{ IU/mL} 0.3 to 0.7 IU/mL . Completely unaffected by acute phase reactants, lupus anticoagulants, or contact factor deficiencies.

Specific Reversal Agent: Protamine Sulfate .

A strongly basic, positively charged polycationic peptide derived from salmon sperm. Rapidly binds strongly acidic, negatively charged heparin molecules via electrostatic interactions, forming a stable, inert salt devoid of anticoagulant activity.

Dosing: 1 mg 1\text{ mg} 1 mg of protamine sulfate neutralizes approximately 100 USP units 100\text{ USP units} 100 USP units of UFH .

2. Low-Molecular-Weight Heparin (LMWH - Enoxaparin, Dalteparin)

Mechanism: Produced by chemical or enzymatic depolymerization of UFH (mean molecular weight 4,000 to 5,000 Da). Most polysaccharide chains contain < 18 <18 < 18 saccharides; they retain the pentasaccharide sequence required to bind AT and inhibit FXa, but are too short to form the bridging complex with thrombin. This yields a predominant 3 : 1 to 4 : 1 3:1\text{ to }4:1 3 : 1 to 4 : 1 anti-Factor Xa to anti-Factor IIa ratio .

Laboratory Monitoring Principles:

High subcutaneous bioavailability and predictable renal clearance; routine coagulation monitoring is NOT required for standard patients .

Indications for Monitoring: Severe renal impairment ( eGFR < 30 mL/min \text{eGFR} < 30\text{ mL/min} eGFR < 30 mL/min ), pregnancy, morbid obesity ( BMI ≥ 40 kg/m 2 \text{BMI} \ge 40\text{ kg/m}^2 BMI ≥ 40 kg/m 2 ), pediatrics, or unexpected bleeding/thrombosis.

Mandatory Monitoring Method: Peak Chromogenic Anti-Xa Assay (LMWH-Calibrated) drawn precisely 4 hours post-subcutaneous injection .

Therapeutic Targets:

Twice-Daily (BID) Therapeutic Dosing: 0.6 to 1.0 IU/mL 0.6\text{ to }1.0\text{ IU/mL} 0.6 to 1.0 IU/mL .

Once-Daily (QD) Therapeutic Dosing: 1.0 to 2.0 IU/mL 1.0\text{ to }2.0\text{ IU/mL} 1.0 to 2.0 IU/mL .

Prophylactic Dosing: 0.2 to 0.4 IU/mL 0.2\text{ to }0.4\text{ IU/mL} 0.2 to 0.4 IU/mL .

Crucial Rule: Standard PT and aPTT are completely insensitive to therapeutic levels of LMWH and cannot be used for monitoring.

Reversal: Protamine Sulfate provides only partial reversal (~60%) , fully neutralizing anti-IIa activity while anti-Xa activity persists due to poor binding to short polysaccharide chains.

3. Synthetic Pentasaccharide (Fondaparinux)

Mechanism: Chemically synthesized pentasaccharide sequence that selectively binds antithrombin, accelerating the neutralization of Factor Xa with zero anti-Factor IIa activity .

HIT Safety: Does not bind Platelet Factor 4 (PF4) and does not induce Heparin-Induced Thrombocytopenia (HIT) , making it a safe alternative in patients with a history of HIT.

Monitoring: Specific fondaparinux-calibrated anti-Xa assay (expressed in μ g/mL \mu\text{g/mL} μ g/mL or mg/L \text{mg/L} mg/L ).

Direct Oral Anticoagulants (DOACs) & Direct Thrombin Inhibitors [ DOAC & DTI PHARMACOLOGY ]

  • DRUG CLASS AGENTS MONITORING ASSAY SPECIFIC REVERSAL AGENT
  • ─────────────────────────────────────────────────────────────────────────────────────────────────────────────
  • Direct FXa Rivaroxaban (Xarelto) Drug-Specific Calibrated Andexanet alfa (Andexxa)
  • Inhibitors Apixaban (Eliquis) Chromogenic Anti-Xa (ng/mL) (Recombinant decoy FXa)
  • Edoxaban (Savaysa)
  • Direct FIIa Dabigatran (Pradaxa) Dilute Thrombin Time (dTT) Idarucizumab (Praxbind)
  • Inhibitors (Oral) Ecarin Clotting Time (ECT) (Humanized Fab Fragment)
  • Direct FIIa Argatroban (Hepatic clear) Routine aPTT (1.5–2.5x) None (Discontinue drug;
  • Inhibitors (IV) Bivalirudin (Renal clear) ECT / ACT short half-life 25–45 min)
  • 1. Direct Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban)

Mechanism: Small-molecule, reversible, competitive active-site inhibitors that selectively block both free Factor Xa and prothrombinase clot-bound Factor Xa independent of antithrombin.

Laboratory Impact & Monitoring:

Prolongs PT and aPTT in a variable, non-linear, reagent-dependent manner (PT is more sensitive to rivaroxaban; aPTT and PT are relatively insensitive to apixaban). PT/INR and aPTT CANNOT be used for quantification.

When quantitative assessment is required (e.g., life-threatening bleeding, emergent surgery, suspected overdose, or acute renal failure), drug-specific calibrated Chromogenic Anti-Xa Assays reporting drug concentrations in ng/mL \text{ng/mL} ng/mL must be utilized.

Specific Reversal Agent: Andexanet Alfa (Andexxa)

A recombinant, modified human Factor Xa decoy protein that lacks the membrane-anchoring Gla domain and contains a catalytic Ser-to-Ala mutation rendering it enzymatically inactive.

High-affinity decoy that binds and sequesters circulating direct FXa inhibitors (apixaban, rivaroxaban) and LMWH-AT complexes, rapidly restoring endogenous Factor Xa activity.

  • 2. Direct Thrombin (Factor IIa) Inhibitors
  • Oral Agent: Dabigatran Etexilate (Pradaxa)

Mechanism: Hydrolyzed in vivo to active dabigatran, a reversible, competitive inhibitor that binds the catalytic active site of free and clot-bound Thrombin (Factor IIa) , blocking fibrinogen cleavage, FXIII activation, and platelet activation.

Laboratory Monitoring:

Routine Thrombin Time (TT): Exquisitely sensitive; a normal TT excludes clinically relevant dabigatran, but therapeutic levels render TT infinitely prolonged ( > 150 seconds >150\text{ seconds} > 150 seconds ), providing no quantitative differentiation.

Dilute Thrombin Time (dTT / Hemoclot): Patient plasma is diluted and tested against standardized thrombin; clotting time exhibits linear correlation with dabigatran concentration ( ng/mL \text{ng/mL} ng/mL ).

Ecarin Clotting Time (ECT): Uses Echis carinatus snake venom metalloproteinase (ecarin) to cleave prothrombin into meizothrombin, which is directly inhibited by dabigatran in a linear fashion.

Specific Reversal Agent: Idarucizumab (Praxbind)

A humanized monoclonal antibody Fab fragment that binds dabigatran and its metabolites with an affinity approximately 350 times higher than that of thrombin .

Administered intravenously ( 5 g 5\text{ g} 5 g total dose), idarucizumab binds free and protein-bound dabigatran within minutes, immediately normalizing the dTT and restoring hemostasis without procoagulant rebound.

Parenteral Agents: Argatroban and Bivalirudin

Argatroban: Synthetic L-arginine derivative that univalently binds the catalytic active site of thrombin. Metabolized entirely by the liver (biliary excretion) ; choice agent for anticoagulation in patients with acute Heparin-Induced Thrombocytopenia (HIT) with renal insufficiency .

Bivalirudin: Synthetic 20-amino acid peptide analogue of hirudin that bivalently binds both the catalytic active site and exosite 1 of thrombin. Cleaved enzymatically by thrombin and cleared renally (~20%); choice agent in HIT patients with severe hepatic failure or undergoing percutaneous coronary intervention (PCI).

Monitoring: Monitored via routine aPTT (therapeutic target: 1.5 to 2.5 times patient baseline) .

Vitamin K Antagonists (Warfarin / Coumadin) [ WARFARIN REVERSAL CASCADE ]

  • LIFE-THREATENING BLEEDING / URGENT SURGERY (INR > 2.0)
  • │
  • ┌──────────────────────────────┴──────────────────────────────┐
  • ▼ ▼
  • [ IMMEDIATE FACTOR REPLACEMENT ] [ SUSTAINED HEPATIC RECOVERY ]
  • 4-Factor Prothrombin Complex Concentrate Intravenous Vitamin K1 (Phytonadione)
  • (4F-PCC / Kcentra: FII, FVII, FIX, FX, PC, PS) (5 to 10 mg Slow IV Infusion)
  • │ │
  • ▼ ▼
  • Normalizes INR within 15–30 Minutes Stimulates de novo factor synthesis
  • (Biological half-life 6–12 hours) over 6–24 hours to prevent rebound INR rise
  • 1. Mechanism of Action

Warfarin acts by competitively inhibiting Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) , blocking the recycling of inactive vitamin K 2,3-epoxide back to active vitamin K hydroquinone ( K H 2 KH_2 K H 2 ​ ).

Depletes the reduced K H 2 KH_2 K H 2 ​ cofactor required by γ \gamma γ -glutamyl carboxylase, resulting in the hepatic synthesis of uncarboxylated, inactive PIVKA forms of Factors II, VII, IX, and X , as well as natural anticoagulants Protein C and Protein S .

2. Clinical Monitoring

Monitored exclusively via Prothrombin Time (PT) reported as International Normalized Ratio (INR) .

Standard Therapeutic Target: INR 2.0 to 3.0 \text{INR } 2.0\text{ to }3.0 INR 2.0 to 3.0 (DVT, PE, Atrial Fibrillation, bioprosthetic valves).

High-Intensity Target: INR 2.5 to 3.5 \text{INR } 2.5\text{ to }3.5 INR 2.5 to 3.5 (Mechanical prosthetic mitral valves).

3. Evidence-Based Reversal Strategies

Urgent / Life-Threatening Major Bleeding (or Emergency Major Surgery):

4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra): Contains concentrated, non-activated Factors II, VII, IX, and X , along with antithrombotic regulatory Protein C and Protein S . Normalizes INR within 15 to 30 minutes without the volume overload risk of Fresh Frozen Plasma (FFP).

Intravenous Vitamin K1 (Phytonadione, 5–10 mg IV): Administered concurrently with 4F-PCC. While 4F-PCC provides instantaneous factor levels, its infused factors clear with physiological half-lives (FVII clears in ~6 hours); IV Vitamin K1 stimulates sustained de novo hepatic synthesis of functional factors over the subsequent 6–24 hours, preventing late rebound INR elevations.

Elevated INR without Major Bleeding:

INR 4.5 to 10.0 \text{INR } 4.5\text{ to }10.0 INR 4.5 to 10.0 (no bleeding): Withhold 1–2 doses of warfarin, monitor INR, and resume at adjusted dose.

INR > 10.0 \text{INR } > 10.0 INR > 10.0 (no bleeding): Withhold warfarin and administer low-dose oral Vitamin K1 (2.5 to 5.0 mg) ; oral route is safe, highly effective, and avoids anaphylactoid risks associated with rapid IV administration.

Comprehensive Comparative Pharmacology & Monitoring Summary

Anticoagulant Drug Class Specific Clinical Agents Primary Molecular Target Monitoring Laboratory Assay Therapeutic Target Range Primary Elimination Route Specific Reversal Agent(s)

Unfractionated Heparin (UFH) Porcine unfractionated heparin Indirect: Thrombin (IIa) & FXa ( 1 : 1 1:1 1 : 1 ratio via AT) aPTT or Chromogenic Anti-Xa (UFH) aPTT: 1.5 – 2.5 × 1.5\text{--}2.5\times 1.5 – 2.5 × baseline; Anti-Xa: 0.3 – 0.7 IU/mL 0.3\text{--}0.7\text{ IU/mL} 0.3 – 0.7 IU/mL Reticuloendothelial / Hepatic clearance Protamine Sulfate ( 1 mg / 100 U UFH 1\text{ mg} / 100\text{ U UFH} 1 mg /100 U UFH )

Low-Molecular-Weight Heparin (LMWH) Enoxaparin (Lovenox), Dalteparin (Fragmin) Indirect: FXa > > > IIa ( 4 : 1 4:1 4 : 1 ratio via AT) Peak Chromogenic Anti-Xa (LMWH) (4h post-dose) BID: 0.6 – 1.0 IU/mL 0.6\text{--}1.0\text{ IU/mL} 0.6 – 1.0 IU/mL ; QD: 1.0 – 2.0 IU/mL 1.0\text{--}2.0\text{ IU/mL} 1.0 – 2.0 IU/mL Renal clearance (monitored if CrCl < 30 \text{CrCl} < 30 CrCl < 30 ) Protamine Sulfate (Partial reversal ~60%)

Synthetic Pentasaccharide Fondaparinux (Arixtra) Indirect: FXa only via AT (No anti-IIa; no HIT) Calibrated Fondaparinux Anti-Xa Prophylactic: 0.2 – 0.4 mg/L 0.2\text{--}0.4\text{ mg/L} 0.2 – 0.4 mg/L ; Therapeutic: 0.5 – 1.5 mg/L 0.5\text{--}1.5\text{ mg/L} 0.5 – 1.5 mg/L Renal clearance (contraindicated if CrCl < 30 \text{CrCl} < 30 CrCl < 30 ) None specific (Andexanet off-label)

Direct Oral FXa Inhibitors (DOACs) Rivaroxaban (Xarelto), Apixaban (Eliquis), Edoxaban Direct: Active site of free & bound FXa Drug-Specific Calibrated Anti-Xa ( ng/mL \text{ng/mL} ng/mL ) Variable by indication ( 50 – 300 ng/mL 50\text{--}300\text{ ng/mL} 50 – 300 ng/mL ) Dual Renal / Hepatic-Biliary Andexanet Alfa (Recombinant modified decoy FXa)

Direct Oral Thrombin Inhibitor Dabigatran (Pradaxa) Direct: Active site of free & bound Thrombin (IIa) Dilute Thrombin Time (dTT) or ECT Peak: 100 – 400 ng/mL 100\text{--}400\text{ ng/mL} 100 – 400 ng/mL ; Trough: 30 – 120 ng/mL 30\text{--}120\text{ ng/mL} 30 – 120 ng/mL Renal clearance ( 80 % 80\% 80% ) Idarucizumab (Praxbind Fab fragment, 5 g IV 5\text{ g IV} 5 g IV )

Direct Parenteral DTIs Argatroban, Bivalirudin (Angiomax) Direct: Active site of Thrombin (IIa) Routine aPTT (or ECT/ACT) aPTT: 1.5 – 2.5 × 1.5\text{--}2.5\times 1.5 – 2.5 × baseline Argatroban: Hepatic ; Bivalirudin: Renal / Proteolytic None specific (Short t 1 / 2 t_{1/2} t 1/2 ​ 25 – 45 min 25\text{--}45\text{ min} 25 – 45 min )

Vitamin K Antagonist (VKA) Warfarin (Coumadin) VKORC1 (depletes active FII, VII, IX, X, PC, PS) Prothrombin Time / INR INR 2.0 – 3.0 ; (Mechanical mitral: 2.5 – 3.5 ) Hepatic (CYP2C9 / CYP3A4) 4F-PCC (Kcentra) + Intravenous Vitamin K1